Circulating FGF-23 Is Associated With Increased Risk of Osteoporosis and Fractures in Hemodialysis Patients: A Prospective Observational Study

IF 2.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of Clinical Practice Pub Date : 2024-10-23 DOI:10.1155/2024/1070492

Dong Liu, Hongyan Yang, Qirong Liao, Baocao Chang, Weiwei Zhang, Xiaoxiong Li, Jinping Li, Mingliang Hou, Linqiu Ma, Yating Liu, Jing Lu, Rui Zhou

{"title":"Circulating FGF-23 Is Associated With Increased Risk of Osteoporosis and Fractures in Hemodialysis Patients: A Prospective Observational Study","authors":"Dong Liu, Hongyan Yang, Qirong Liao, Baocao Chang, Weiwei Zhang, Xiaoxiong Li, Jinping Li, Mingliang Hou, Linqiu Ma, Yating Liu, Jing Lu, Rui Zhou","doi":"10.1155/2024/1070492","DOIUrl":null,"url":null,"abstract":"<div>\n Background and Objective: It is still controversial whether circulating fibroblast growth factor 23 (FGF-23) can be used as a biomarker for the diagnosis of osteoporosis and fractures in patients with chronic kidney disease undergoing hemodialysis. We investigated the association of circulating FGF-23 concentrations with an increased risk of osteoporosis and fractures of hemodialysis patients in the prospective study.\n Methods: These data were collected in adult patients with hemodialysis in China from January 1 to December 30, 2016, and patients were followed up for 3.5 years. The association of circulating FGF-23 with the risk of osteoporosis and fractures was analyzed by multivariate analysis.\n Results: The study included 1788 hemodialysis patients, with a median age of 56 years (50–64 years) and a female population of 54.5%. Of 1788 patients, 389 (21.8%) developed osteoporosis and 207 (11.6%) developed fractures. High concentrations of FGF-23 were significantly related to osteoporosis and fractures and were significantly related to different types of fractures (vertebral fractures, nonvertebral fractures, and hip fractures). Adjusted for all potential risk factors, high concentrations of FGF-23 were associated with the risk of osteoporosis or fractures.\n Conclusion: High concentrations of circulating FGF-23 were associated with the risk of osteoporosis and fractures, including vertebral fractures and hip fractures. FGF-23, along with bALP, CTX, and OC, may be used as a serum biomarker for predicting the risk of osteoporosis and fractures in patients with hemodialysis.\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2024 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/1070492","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/1070492","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Objective: It is still controversial whether circulating fibroblast growth factor 23 (FGF-23) can be used as a biomarker for the diagnosis of osteoporosis and fractures in patients with chronic kidney disease undergoing hemodialysis. We investigated the association of circulating FGF-23 concentrations with an increased risk of osteoporosis and fractures of hemodialysis patients in the prospective study.

Methods: These data were collected in adult patients with hemodialysis in China from January 1 to December 30, 2016, and patients were followed up for 3.5 years. The association of circulating FGF-23 with the risk of osteoporosis and fractures was analyzed by multivariate analysis.

Results: The study included 1788 hemodialysis patients, with a median age of 56 years (50–64 years) and a female population of 54.5%. Of 1788 patients, 389 (21.8%) developed osteoporosis and 207 (11.6%) developed fractures. High concentrations of FGF-23 were significantly related to osteoporosis and fractures and were significantly related to different types of fractures (vertebral fractures, nonvertebral fractures, and hip fractures). Adjusted for all potential risk factors, high concentrations of FGF-23 were associated with the risk of osteoporosis or fractures.

Conclusion: High concentrations of circulating FGF-23 were associated with the risk of osteoporosis and fractures, including vertebral fractures and hip fractures. FGF-23, along with bALP, CTX, and OC, may be used as a serum biomarker for predicting the risk of osteoporosis and fractures in patients with hemodialysis.

Abstract Image

查看原文本刊更多论文

循环中的 FGF-23 与血液透析患者骨质疏松症和骨折风险增加有关：一项前瞻性观察研究

背景与目的：循环成纤维细胞生长因子 23（FGF-23）能否作为诊断接受血液透析的慢性肾病患者骨质疏松症和骨折的生物标志物仍存在争议。我们在前瞻性研究中调查了循环 FGF-23 浓度与血液透析患者骨质疏松症和骨折风险增加之间的关系。研究方法这些数据收集于2016年1月1日至12月30日期间中国的成年血液透析患者，并对患者进行了为期3.5年的随访。通过多变量分析法分析了循环FGF-23与骨质疏松症和骨折风险的关系。研究结果研究共纳入 1788 名血液透析患者，中位年龄为 56 岁（50-64 岁），女性占 54.5%。在 1788 名患者中，389 人（21.8%）出现骨质疏松症，207 人（11.6%）出现骨折。高浓度的 FGF-23 与骨质疏松症和骨折显著相关，并且与不同类型的骨折（椎骨骨折、非椎骨骨折和髋部骨折）显著相关。对所有潜在风险因素进行调整后，高浓度的 FGF-23 与骨质疏松症或骨折风险相关。结论高浓度的循环 FGF-23 与骨质疏松症和骨折（包括椎骨骨折和髋部骨折）的风险有关。FGF-23以及bALP、CTX和OC可作为血清生物标志物，用于预测血液透析患者骨质疏松症和骨折的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Practice 医学-医学：内科

CiteScore

5.30

自引率

0.00%

发文量

274

审稿时长

3-8 weeks

期刊介绍： IJCP is a general medical journal. IJCP gives special priority to work that has international appeal. IJCP publishes: Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion] Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion] Study design and interpretation. Example. [Always peer reviewed] Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed] Meta-analyses. [Always peer reviewed] Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed] Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed] ''How to…'' papers. Example. [Always peer reviewed] Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed] Letters. [Peer reviewed at the editor''s discretion] International scope IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.